drugset / Trial / NCT00775463

Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine

NCT00775463

Phase 2 Completed 148 enrolled United Therapeutics
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the effect of treprostinil diethanolamine (UT-15C) sustained release tablets(compared to placebo) on digital ulcers in patients with scleroderma. Treprostinil diethanolamine is an analog of prostacyclin. Prostacyclin is a naturally occuring substance produced by the cells of blood vessels that inhibits platelet aggregation, induces vasodilation, and suppresses smooth muscle proliferation. Improvement in blood flow in lower limbs and fingers would be anticipated to result in a reduction in ischemic pain, Raynaud's phenomenon and promote healing of digital ulcers and other ischemic wounds.

Timeline

Start
2009-05
Primary completion
2011-03
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Treprostinil Other / unclassified 16 mg Oral

Indications